Sugi Predict

Sugi Predict / Compounds / SCHEMBL336648

SCHEMBL336648

SCHEMBL336648

O=C(O)CCCCCCCCCCC(=O)ON1C(=O)CCC1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 4/20 0.43
▸ LMNA P02545 2/20 0.43
▸ NFKB1 P19838 1/20 0.43
▸ PMP22 Q01453 1/20 0.43
▸ PTGS1 P23219 4/20 0.40
▸ PTGS2 P35354 4/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ GAA P10253 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ F13A1 P00488 3/20 0.38
▸ GPR84 Q9NQS5 3/20 0.38
▸ FFAR1 O14842 1/20 0.38
▸ FFAR4 Q5NUL3 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.37
▸ PPARG P37231 3/20 0.36
▸ PPARD Q03181 3/20 0.36
▸ PPARA Q07869 3/20 0.36
▸ HDAC11 Q96DB2 2/20 0.36
▸ TDP1 Q9NUW8 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL336568 1.00 TSHR (0.43) TSHRLMNANFKB1PMP22PTGS1
SCHEMBL337031 1.00 TSHR (0.43) TSHRLMNANFKB1PMP22PTGS1
SCHEMBL1230060 1.00 TSHR (0.43) TSHRLMNANFKB1PMP22PTGS1
SCHEMBL25406852 1.00 TSHR (0.43) TSHRLMNANFKB1PMP22PTGS1
SCHEMBL25408775 1.00 TSHR (0.43) TSHRLMNANFKB1PMP22PTGS1
SCHEMBL25408793 1.00 TSHR (0.43) TSHRLMNANFKB1PMP22PTGS1
SCHEMBL25408300 1.00 TSHR (0.43) TSHRLMNANFKB1PMP22PTGS1
SCHEMBL25407766 1.00 TSHR (0.43) TSHRLMNANFKB1PMP22PTGS1
SCHEMBL905403 1.00 TSHR (0.43) TSHRLMNANFKB1PMP22PTGS1
SCHEMBL337556 1.00 TSHR (0.43) TSHRLMNANFKB1PMP22PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1840134-B1 GLP-1 derivatives NOVO NORDISK AS (DK) 2016-04-13 — — EP disclosed
US-8097698-B2 Derivatives of GLP-1 analogs NOVO NORDISK A/S (DK) 2012-01-17 — — US disclosed
US-20110053839-A1 GLP-1 Derivatives II NOVO NORDISK A/S (DK) 2011-03-03 — — US disclosed
EP-1056775-B1 GLP-1 DERIVATIVES OF GLP-1 AND EXENDIN WITH PROTRACTED PROFILE OF ACTION NOVO NORDISK AS (DK) 2010-04-28 — — EP disclosed
EP-1060191-B1 DERIVATIVES OF GLP-1 ANALOGS NOVO NORDISK AS (DK) 2010-04-28 — — EP disclosed
US-20090176700-A1 Derivatives Of GLP-1 Analogs NOVO NORDISK A/S (DK) 2009-07-09 — — US disclosed
US-7411039-B2 GLP-2 compounds, formulations, and uses thereof NOVO NORDISK A/S (DK) 2008-08-12 — — US disclosed
US-20080103097-A1 GLP-1 derivatives II NOVO NORDISK A/S (DK) 2008-05-01 — — US disclosed
EP-1840134-A2 GLP-1 derivatives NOVO NORDISK A/S (DK) 2007-10-03 — — EP disclosed
EP-1826216-A1 Glp-1 derivatives NOVO NORDISK A/S (DK) 2007-08-29 — — EP disclosed
US-20030199451-A1 Combination therapy using a dual PPAR-a/PPAR-y activator and a GLP-1 derivative for the treatment of metabolic syndrome and related diseases and disorders HIGH POINT PHARMACEUTICALS, LLC 2003-10-23 — — US disclosed
US-6458924-B2 POLYPEPTIDE DRUG; ANTIDIABETIC AGENT; Liraglutide NOVO NORDISK A/S (DK) 2002-10-01 — — US disclosed
US-20010011071-A1 DERIVATIVES OF GLP-1 ANALOGS KNUDSEN LISELOTTE BJERRE (DK) 2001-08-02 — — US disclosed
US-6268343-B1 HUMAN GLUCAGON-LIKE PEPTIDE-1; MORE PROTRACTED PROFILE OF ACTION THAN THE PARENT PEPTIDES; TREATING DIABETES AND OBESITY; Liraglutide NOVO NORDISK A/S (DK) 2001-07-31 — — US disclosed
EP-1061946-A1 GLP-1 DERIVATIVES WITH HELIX-CONTENT EXCEEDING 25 %, FORMING PARTIALLY STRUCTURED MICELLAR-LIKE AGGREGATES NOVO NORDISK A/S (DK) 2000-12-27 — — EP disclosed
EP-1060191-A1 DERIVATIVES OF GLP-1 ANALOGS NOVO NORDISK A/S (DK) 2000-12-20 — — EP disclosed
EP-0944648-A1 GLP-1 DERIVATIVES NOVO NORDISK A/S (DK) 1999-09-29 — — EP disclosed
WO-1999043706-A1 DERIVATIVES OF GLP-1 ANALOGS NOVO NORDISK A/S (DK) 1999-09-02 — — WO disclosed
WO-1999043341-A1 GLP-1 DERIVATIVES WITH HELIX-CONTENT EXCEEDING 25 %, FORMING PARTIALLY STRUCTURED MICELLAR-LIKE AGGREGATES NOVO NORDISK A/S (DK) 1999-09-02 — — WO disclosed
WO-1998008871-A1 GLP-1 DERIVATIVES NOVO NORDISK A/S (DK) 1998-03-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176700-A1 Derivatives Of GLP-1 Analogs GLP1R, GIPR, IAPP TSHR 253/4885LMNA 1808/4885NFKB1 3751/4885
US-20030199451-A1 Combination therapy using a dual PPAR-a/PPAR-y activator and a GLP-1 derivative for the treatment of metabolic syndrome and related diseases and disorders GLP1R, PPARG, PPARA TSHR 164/4885LMNA 1431/4885NFKB1 4085/4885
US-20010011071-A1 DERIVATIVES OF GLP-1 ANALOGS GLP1R, GIPR, IAPP TSHR 253/4885LMNA 1808/4885NFKB1 3751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.